Clinical Trial: NCT04231448
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Chipscreen Biosciences, Ltd. |
| Information Provided By: | Chipscreen Biosciences, Ltd. |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2 Double-Expressor Diffuse Large B-cell Lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
- Drug: Tucidinostat
- Drug: Placebo
Other Study ID Numbers
- CDM302
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Chipscreen Biosciences, Ltd. |
| Information Provided By: | Chipscreen Biosciences, Ltd. |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2 Double-Expressor Diffuse Large B-cell Lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
- Drug: Tucidinostat
- Drug: Placebo
Other Study ID Numbers
- CDM302